The hospital will use the SOPHiA DDM™ Platform
to further its work with myeloid disorders and advance the
development of precision medicine
BOSTON and ROLLE, Switzerland, Sept. 29,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, today announced that Shaare Zedek, the largest
multi-disciplinary medical center in Jerusalem, is now live on the SOPHiA DDM™
Platform. The Platform will enable Shaare Zedek to advance its
insights the treatment of myeloid disorders and further develop the
application of precision medicine.
Myeloid disorders affect millions of people worldwide, and while
there are various types and classification of these disorders,
collectively all myeloid disorders originate from hematopoietic
disruptions in the myeloid lineage1. Because of the wide
range of disorders and the complexity of these genetic mutations,
treatment and therapy techniques evolve rapidly and are highly
dependent on timely, cost-effective, and reliable sequencing
strategies.
Shaare Zedek Medical Center has been providing top-level medical
research and care for the people of Jerusalem since 1902. Today the hospital's
name has become synonymous with advanced medicine, compassionate
care, and many of the brightest medical minds in Israel. The use of SOPHiA GENETICS technology
will allow Shaare Zedek to continue leading the way in Israel with cutting-edge technology aligned
with the latest guidelines from the European Hematology Association
(EHA).
"The last several years have shown rapid progress in targeted
therapies for myeloid disorders," said Kevin Puylaert, Managing
Director, EMEA, SOPHiA GENETICS. "With that progress has come an
increase in international recommendations that can be challenging
to keep up with. The implementation of the SOPHiA DDM™ Platform by
Shaare Zedek will allow the hospital to keep pace with the progress
while advancing its research to best serve its community."
Molecular profiling via next-generation sequencing (NGS) is
widely used to investigate the pathogenic variants causing
different myeloid malignancies. However, NGS produces a vast amount
of complex data. The SOPHiA DDM™ Platform is an NGS-based
application that uses artificial intelligence (AI) to efficiently
analyze and interpret raw NGS data for researchers. The Platform
provides streamlined insights in a matter of days, enabling
clinical researchers to make data-driven recommendations more
quickly.
In addition to quickly providing analysis and insights, the
SOPHiA DDM™ Platform makes it easier for researchers to obtain
reproducible data that can help to accelerate their studies. With
the SOPHiA DDM™ Platform, Shaare Zedek Medical Center will retain
complete ownership of its database, supporting the research team as
it continues to increase its expertise.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on X (formerly known as
Twitter), LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X (formerly known as Twitter), LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
1 https://www.sophiagenetics.com/clinical/oncology/blood-cancers/myeloid-malignancies/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shaare-zedek-medical-center-uses-sophia-genetics-to-advance-research-of-myeloid-disorders-301942449.html
SOURCE SOPHiA GENETICS